Korean drug pricing policy lacking efficiency and accessibility.

Published: 2006-06-12 07:00:00

Updated: 2006-06-12 07:00:00

An opinion has been suggested that the drug pricing policy in Korea had kept relatively underestimating its economic efficiency and accessability compared to other advanced countries. Accordingly, the positive list system for the drug prices to be determined in its economic value as a cost and be...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK